Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of CAEL-101/Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement

NCT07615270 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT07615270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07615270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of CAEL-101/Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
July 31, 2028
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis